What is Arrayus?
Arrayus Technologies Inc. operates at the intersection of advanced medical imaging and therapeutic intervention. The company specializes in a non-invasive focused ultrasound platform designed to replace conventional scalpel-based surgical procedures. By integrating high-precision MRI image guidance with real-time monitoring, the platform offers a sophisticated outpatient alternative for patients facing complex oncological conditions, including those previously deemed inoperable. Under the leadership of Dr. Kullervo Hynynen, a recognized authority in focused ultrasound, the firm is effectively bridging the gap between diagnostic imaging and active treatment. This technological synergy allows for a more precise, efficient, and patient-centric approach that complements standard-of-care modalities such as chemotherapy and radiation therapy, thereby enhancing the overall efficacy of cancer treatment protocols.
How much funding has Arrayus raised?
Arrayus has raised a total of $1.9M across 1 funding round:
Grant
$1.9M
Grant (2023): $1.9M with participation from Government of Canada
Key Investors in Arrayus
Government of Canada
The Government of Canada acts as a federal entity providing public funding and support for innovative research and development initiatives that align with national healthcare and technological advancement goals.
What's next for Arrayus?
With the recent strategic investment, Arrayus is poised to scale its clinical validation efforts and refine its therapeutic delivery systems. The company's forward-looking strategy focuses on expanding the versatility of its ultrasound platform to address a broader spectrum of oncological indications. By prioritizing research-driven growth and strategic collaborations, Arrayus aims to solidify its market position as a leader in non-invasive surgical alternatives. The current funding trajectory suggests a clear path toward commercialization, with the firm likely to focus on regulatory milestones and the expansion of its clinical trial infrastructure to demonstrate long-term patient outcomes and cost-effectiveness in the healthcare ecosystem.
See full Arrayus company page
